-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Kv3vG5B9z/+ebvfMewkwhbdq8XRPJ3hF8CjakwAMOwmWndFkkrM96UBhZrD7Dymz
 ucOZkJmGpR/yUilnQkEwfA==

<SEC-DOCUMENT>0000891618-00-001861.txt : 20000331
<SEC-HEADER>0000891618-00-001861.hdr.sgml : 20000331
ACCESSION NUMBER:		0000891618-00-001861
CONFORMED SUBMISSION TYPE:	RW
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20000330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LYNX THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000913275
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				943161073
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		RW
		SEC ACT:		
		SEC FILE NUMBER:	333-32450
		FILM NUMBER:		586194

	BUSINESS ADDRESS:	
		STREET 1:		3832 BAY CENTER PL
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		5106709300

	MAIL ADDRESS:	
		STREET 1:		3832 BAY CENTER PLACE
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>RW
<SEQUENCE>1
<DESCRIPTION>REQUEST FOR WITHDRAWAL
<TEXT>

<PAGE>   1
                      [LYNX THERAPEUTICS, INC. LETTERHEAD]


March 30, 2000


Securities and Exchange Commission
450 Fifth Street, N.W.
Judiciary Plaza
Washington, D.C. 20549

Re:  Lynx Therapeutics, Inc.
     Registration Statement on Form S-3 (No. 333-32450)
     Application for Withdrawal under Rule 477

Ladies and Gentlemen:

The undersigned registrant hereby makes application, pursuant to Rule 477 under
the Securities Act of 1933, as amended, to withdraw the above-referenced
Registration Statement on Form S-3 that was filed with the Securities and
Exchange Commission on March 14, 2000. Please note that the Registration
Statement has not yet been declared effective. This application is made on the
grounds that based on current market conditions, the undersigned registrant has
determined that it is not advisable at this time to proceed with the proposed
offering.

If you should have any questions regarding this application, please contact the
undersigned at (510) 670-9325 or Gianna M. Bosko of Cooley Godward LLP at (650)
843-5045.

Sincerely,

LYNX THERAPEUTICS, INC.

/s/ EDWARD C. ALBINI
- ------------------------
Edward C. Albini
Chief Financial Officer
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----